Orient Europharma (4120) reported revenue of NT$419.8 million for Oct 2026, -4.2% year on year and -3.6% from the previous month. Revenue for Jan–Oct 2026 was NT$3.95 billion (+3.0% year on year).
In Oct 2026, it ranked No. 22 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$419.8 million | -4.2% | -3.6% |
| Sep 2026 | NT$435.3 million | +10.0% | +21.3% |
| Aug 2026 | NT$358.9 million | -3.1% | -9.3% |
| Jul 2026 | NT$395.8 million | +13.3% | -11.7% |
| Jun 2026 | NT$448 million | +25.1% | +28.4% |
| May 2026 | NT$348.8 million | -11.0% | -11.8% |
| Apr 2026 | NT$395.3 million | +5.2% | -0.9% |
| Mar 2026 | NT$399 million | +7.4% | +31.1% |
| Feb 2026 | NT$304.5 million | -14.9% | -31.6% |
| Jan 2026 | NT$445.5 million | +4.4% | +15.0% |
| Dec 2025 | NT$387.2 million | +14.4% | +4.5% |
| Nov 2025 | NT$370.7 million | -7.3% | -15.4% |
| Oct 2025 | NT$438.1 million | +13.5% | +10.7% |
| Sep 2025 | NT$395.7 million | +17.0% | +6.9% |
| Aug 2025 | NT$370.2 million | -2.2% | +6.0% |
| Jul 2025 | NT$349.3 million | -0.9% | -2.5% |
| Jun 2025 | NT$358.1 million | +3.4% | -8.7% |
| May 2025 | NT$392.2 million | +11.0% | +4.3% |
| Apr 2025 | NT$375.9 million | -2.2% | +1.2% |
| Mar 2025 | NT$371.6 million | +10.3% | +3.8% |
| Feb 2025 | NT$357.9 million | +10.3% | -16.1% |
| Jan 2025 | NT$426.7 million | -3.6% | +26.1% |
| Dec 2024 | NT$338.4 million | -15.8% | -15.4% |
| Nov 2024 | NT$399.8 million | -3.0% | +3.6% |
| Oct 2024 | NT$385.9 million | +0.3% | +14.1% |
Jan–Oct 2026 cumulative: NT$3.95 billion (+3.0% YoY)
Other Biotech & Medical companies
Compare with peers: Orient Europharma vs PEC / Orient Europharma vs Lotus Pharm / Orient Europharma vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16